| Revenue growth | Q2 +21%, H1 +23% YoY |
|---|---|
| Margins | Q2 EBITDA margin 37.2% (+~70bps YoY); PAT margin down to 26.3% |
| Demand visibility | Healthy demand across Pharma, Food & Nutrition, Specialty; AbsorBis momentum |
| Management confidence | Upbeat; 'well positioned to sustain growth momentum' |
Growth
H1 revenue Rs355.0cr (+23%), EBITDA Rs128.1cr (+29%), PAT Rs92.4cr (+18%). Q2 PAT margin 26.3% vs 28.7%.
Outlook
Nandesari commercial supplies from H2FY27. Dahej Phase 1 (25,000 MTPA) by Mar-2027. Evaluating extra 100,000 MTPA. Offtake deals targeted by Q4FY27.
Risks
Elevated logistics costs and global uncertainties. Net working capital days rose to 215 from 213 in FY26. Trade receivables Rs246.1cr.
Investor Presentation filed with BSE, NSE: SUDEEPPHRM. Summary written with AI assistance from the document.
Sudeep Pharma Ltd: key numbers
- Share price
- ₹1,119.00
- Market cap
- ₹12,639 Cr
- Revenue (annual)
- ₹642.3 Cr
- Net profit (annual)
- ₹172.9 Cr
- P/E (TTM)
- 67.1×Sector 46.1×
- Promoter holding
- 76.15%+0.00% QoQ
- FII holding
- 2.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudeep Pharma Ltd
All →Sudeep Pharma Q2 FY27 Results: Net Profit ₹51.8 Cr, Up 10.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹196.7 Cr (+20.9% YoY) and net profit of ₹51.8 Cr (+10.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹51.8 Cr · +10.7% YoY
Sudeep Pharma Capacity Expansion
Sudeep Pharma received FDA approval for its new 51,200 MT greenfield plant at Nandesari, Gujarat. Commercial operations are expected to commence in H2 FY27 following customer qualification.
- manufacturing capacity
- 51200 MT
Sudeep Pharma Board Meeting Date
Sudeep Pharma has scheduled its Board meeting for 28 October 2026 to approve Q1 and H1 FY27 financial results. No results or monetary figures are disclosed in this intimation.
Sudeep Pharma Other Announcement
The company submitted the mandatory compliance certificate under Regulation 74(5) for the quarter ended September 30, 2026.
Sudeep Pharma Management Change
Mr. Sendhil Pani has ceased to be a Senior Management Personnel of Sudeep Pharma Ltd effective October 2, 2026. This follows the completion of his contractual arrangements.
Sudeep Pharma Other Announcement
Sudeep Pharma cancelled its analyst/investor plant visit scheduled for 23–24 September 2026 due to exigencies. No financial or operational impact is indicated.